Karyopharm Therapeutics Inc (Nasdaq:KPTI), a commercial-stage pharmaceutical company developing novel cancer therapies, announced on Tuesday that it has granted an aggregate of 466 restricted stock units (RSUs) to two newly-hired employees.

These RSU awards were granted as of 31 August 2025 as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU award will vest over three years, with 33.3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

Karyopharm noted that each RSU award will be immediately exercisable in full if, on or before the first anniversary of the consummation of a 'change in control event', the employee's employment is terminated for 'good reason' by the employee or terminated without 'cause' by Karyopharm (as such terms are defined in the 2022 Inducement Stock Incentive Plan, as amended).